Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra De Meyer

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
AIDS (London, England)|December 20, 2007
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients"Gastón Picchio, Sandra De Meyer, Marie-Pierre de Béthune
Antimicrobial Agents and Chemotherapy|September 23, 2015
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed MutantsThierry Verbinnen, Bart Fevery, Leen Vijgen, et al.
Virology Journal|June 3, 2014
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirSandra De Meyer, Anne Ghys, Inge Dierynck, et al.
AIDS Research and Human Retroviruses|February 17, 2015
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012Erkki Lathouwers, Soumi Gupta, Mojgan Haddad, et al.
HIV Research & Clinical Practice|July 28, 2020
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infectionErkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, et al.
Virology Journal|June 2, 2017
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845Leen Vijgen, Kim Thys, An Vandebosch, et al.
HIV Clinical Trials|November 17, 2017
HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studiesErkki Lathouwers, Eric Y Wong, Donghan Luo, et al.
AIDS (London, England)|February 18, 2010
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trialsMonika Peeters, Johan Vingerhoets, Lotke Tambuyzer, et al.
Antiviral Therapy|May 25, 2023
Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ studyJohan Vingerhoets, Ilse Van Dromme, Wilbert van Duijnhoven, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 10, 2009
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trialSandra De Meyer, Andrew Hill, Gaston Picchio, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|December 20, 2007
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients"Gastón Picchio, Sandra De Meyer, Marie-Pierre de Béthune
Antimicrobial Agents and Chemotherapy|September 23, 2015
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed MutantsThierry Verbinnen, Bart Fevery, Leen Vijgen, et al.
Virology Journal|June 3, 2014
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirSandra De Meyer, Anne Ghys, Inge Dierynck, et al.
AIDS Research and Human Retroviruses|February 17, 2015
Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012Erkki Lathouwers, Soumi Gupta, Mojgan Haddad, et al.
HIV Research & Clinical Practice|July 28, 2020
Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infectionErkki Lathouwers, Sareh Seyedkazemi, Donghan Luo, et al.
Virology Journal|June 2, 2017
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845Leen Vijgen, Kim Thys, An Vandebosch, et al.
HIV Clinical Trials|November 17, 2017
HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studiesErkki Lathouwers, Eric Y Wong, Donghan Luo, et al.
AIDS (London, England)|February 18, 2010
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trialsMonika Peeters, Johan Vingerhoets, Lotke Tambuyzer, et al.
Antiviral Therapy|May 25, 2023
Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ studyJohan Vingerhoets, Ilse Van Dromme, Wilbert van Duijnhoven, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 10, 2009
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trialSandra De Meyer, Andrew Hill, Gaston Picchio, et al.
Pageof 6